Skip to main content
. 2019 Aug;16(3):556–564. doi: 10.20892/j.issn.2095-3941.2018.0506

4.

4

Treatment outcomes and overall survival of EGFR-mutant patients with pathogenic germline BRCA mutations treated with EGFR inhibitor. (A) Progression-free survival (PFS) and (B) overall survival (OS) from the day of treatment of 20 patients who received first-generation EGFR inhibitor as first-line treatment.